Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

Laubli, H. P., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 321

PD-1 Protects against Inflammation and Myocyte Damage in T Cell-Mediated Myocarditis

Tarrio, M. L., Grabie, N., Bu, D.-X., Sharpe, A. H., & Lichtman, A. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200389 · Cited by 288

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

Koelzer, V. H., Rothschild, S. I., Zihler, D., Wicki, A., Willi, B., Willi, N., Voegeli, M., Cathomas, G., Zippelius, A., & Mertz, K. D. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0117-1 · Cited by 200

A novel real‐time PCR system for simultaneous detection of human viruses in clinical samples from patients with uncertain diagnoses

Katano, H., Kano, M., Nakamura, T., Kanno, T., Asanuma, H., & Sata, T. (2010) · Journal of Medical Virology · doi:10.1002/jmv.21962 · Cited by 64

Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Mahmood, S. S., Fradley, M. G., Cohen, J. V., Nohria, A., Reynolds, K. L., Heinzerling, L. M., Sullivan, R. J., Damrongwatanasuk, R., Chen, C. L., Gupta, D., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.037 · Cited by 1,608

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

Palaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535

Cardiotoxicity of immune checkpoint inhibitors

Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 247

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review

Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178

Cardiovascular Toxicities Associated with Cancer Immunotherapies

Wang, D. Y., Okoye, G. D., Neilan, T., Johnson, D. B., & Moslehi, J. J. (2017) · Current Cardiology Reports · doi:10.1007/s11886-017-0835-0 · Cited by 161

Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis

Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Delgado, P., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111611 · Cited by 137

Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area

Mir, H. R., Alhussein, M. M., Alrashidi, S., Alzayer, H., Alshatti, A., Valettas, N., Mukherjee, S. D., Nair, V., & Leong, D. P. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.03.012 · Cited by 124

Immune Checkpoint Inhibitor Toxicity

Palmieri, D. J., & Carlino, M. S. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0718-6 · Cited by 126

IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein

Uversky, V. N., Redwan, E. M. M. M., Makis, W., & Rubio‐Casillas, A. (2023) · Vaccines · doi:10.3390/vaccines11050991 · Cited by 127

Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms

Champion, S. N., & Stone, J. R. (2019) · Modern Pathology · doi:10.1038/s41379-019-0363-0 · Cited by 116

Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade

Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115

Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action

Neilan, T. G., Rothenberg, M. L., Amiri‐Kordestani, L., Sullivan, R. J., Steingart, R. M., Gregory, W. W., Hariharan, S., Hammad, T. A., Lindenfeld, J. M., Murphy, M. J., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0157 · Cited by 107

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 109

Co-stimulatory and co-inhibitory pathways in cancer immunotherapy

O’Neill, R., & Cao, X. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.003 · Cited by 105

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology

Chen, D., Huang, W., Wu, V. C., Chang, W., Chen, J., Chuang, C., & Chu, P. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.07.025 · Cited by 96

Cardiac Complications in Immune Checkpoint Inhibition Therapy

Tajiri, K., & Ieda, M. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00003 · Cited by 95

Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling

Xia, W., Zou, C., Chen, H., Xie, C., & Hou, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02778-2 · Cited by 90

T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword

Simons, K. H., de Jong, A., Jukema, J. W., de Vries, M. R., Arens, R., & Quax, P. H. A. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0164-7 · Cited by 89

CD4 + T cells are essential for the development of destructive thyroiditis induced by anti–PD-1 antibody in thyroglobulin-immunized mice

Yasuda, Y., Iwama, S., Sugiyama, D., Okuji, T., Kobayashi, T., Ito, M., Okada, N., Enomoto, A., Ito, S., Yan, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb7495 · Cited by 86

Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance

Mascolo, A., Scavone, C., Ferrajolo, C., Rafaniello, C., Danesi, R., Re, M. D., Russo, A. D., Coscioni, E., Rossi, F., Alfano, R., et al. (2020) · Drug Safety · doi:10.1007/s40264-021-01086-8 · Cited by 81

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature

Agrawal, N., Khunger, A., Vachhani, P. J., Colvin, T. A., Hattoum, A., Spangenthal, E. J., Curtis, A. B., Dy, G. K., Ernstoff, M. S., & Puzanov, I. J. (2019) · Case Reports in Oncology · doi:10.1159/000498985 · Cited by 81

Fatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab

Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 72

Immune checkpoint inhibitor-related myocarditis

Tajiri, K., Aonuma, K., & Sekine, I. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx154 · Cited by 71

Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity

Martínez‐Calle, N., Rodríguez‐Otero, P., Villar, S., Mejías, L. D., Melero, I., Prósper, F., Marinello, P. M., Paiva, B., Idoate, M. A., & Miguel, J. F. S. (2018) · Haematologica · doi:10.3324/haematol.2017.185777 · Cited by 73

Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis

Wang, R., Singaraju, A., Marks, K. E., Shakib, L., Dunlap, G. S., Adejoorin, I., Greisen, S. R., Chen, L., Tirpack, A., Aude, C. A., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1591 · Cited by 77

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., Lorenzo, C. D., & Maurea, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040179 · Cited by 68

Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy

Sobol, I., Chen, C. L., Mahmood, S., & Borczuk, A. (2020) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0447-oa · Cited by 67

Immune-mediated Pericarditis With Pericardial Tamponade During Nivolumab Therapy

de Almeida, D. V. P., Gomes, J. R., Haddad, F. J., & Buzaid, A. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000217 · Cited by 62

Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review

Pradhan, R., Nautiyal, A., & Singh, S. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.07.025 · Cited by 63

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS

Chen, C., Chen, T., Liang, J., Guo, X., Xu, J., Zheng, Y., Guo, Z., Chi, L., Wei, L., Chen, X., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.616505 · Cited by 58

Cardiotoxic mechanisms of cancer immunotherapy – A systematic review

Lobenwein, D., Kocher, F., Dobner, S., Gollmann‐Tepeköylü, C., & Holfeld, J. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.08.033 · Cited by 59

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55

A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies

Guo, C. W., Alexander, M., Dib, Y., Lau, P. K. H., Weppler, A. M., Au‐Yeung, G., Lee, B., Khoo, C. C. H., Mooney, D., Joshi, S. B., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.09.009 · Cited by 55

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51

Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis

Nso, N., Antwi‐Amoabeng, D., Beutler, B. D., Ulanja, M. B., Ghuman, J., Hanfy, A. A., Nimo-Boampong, J., Atanga, S., Doshi, R. P., Enoru, S. T., et al. (2020) · World Journal of Cardiology · doi:10.4330/wjc.v12.i11.584 · Cited by 51

Immune-Related Fulminant Myocarditis in a Patient Receiving Ipilimumab Therapy for Relapsed Chronic Myelomonocytic Leukaemia

Berg, D. D., Vaduganathan, M., Davids, M. S., Alyea, E. P., Torre, M., Padera, R. F., & Nohria, A. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.806 · Cited by 49

Cardiotoxicities associated with immune checkpoint inhibitors

Yang, S., & Asnani, A. H. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.002 · Cited by 49

Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data

Fan, Q., Hu, Y., Yang, C., & Zhao, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105866 · Cited by 49

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases

Matzen, E., Bartels, L. E., Løgstrup, B. B., Madsen, S. H., Stilling, C., & Donskov, F. N. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00114-x · Cited by 47

Cancer therapy-induced cardiotoxicity: mechanisms and mitigations

Shil, S., Kumar, P., & Mumbrekar, K. D. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10531-0 · Cited by 60

Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy

Wang, W., & Cao, X. (2019) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2019031188 · Cited by 43

A Review of Immune-Mediated Adverse Events in Melanoma

Kennedy, L. B., & Salama, A. K. S. (2019) · Oncology and Therapy · doi:10.1007/s40487-019-0096-8 · Cited by 41

Injury-induced myosin-specific tissue-resident memory T cells drive immune checkpoint inhibitor myocarditis

Kalinoski, H. M., Daoud, A. R., Rusinkevich, V., Jurčová, I., Talor, M. V., Welsh, R. A., Hughes, D., Zemanová, K., Stříž, I., Hooper, J. E., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2323052121 · Cited by 40

Therapeutic strategies for virus-negative myocarditis: a comprehensive review

Luca, G. D. D., Campochiaro, C., Sartorelli, S., Peretto, G., & Dagna, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.050 · Cited by 38

Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy

Sanaei, M., Pourbagheri‐Sigaroodi, A., Kaveh, V., Abolghasemi, H., Ghaffari, S. H., Momeny, M., & Bashash, D. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174404 · Cited by 36

Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges

Huertas, R. M., Saavedra, C., Perna, C., Gómez, A. F., & Gordoa, T. A. (2019) · Cancer Management and Research · doi:10.2147/cmar.s185202 · Cited by 33

Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report

Hardy, T., Yin, M., Chavez, J. A., Ivanov, I., Chen, W., Nádasdy, T., & Brodsky, S. V. (2020) · Cardiovascular Pathology · doi:10.1016/j.carpath.2020.107202 · Cited by 31

Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis

Hu, J., Tian, R., Ma, Y., Zhen, H., Ma, X., Su, Q., & Cao, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.645245 · Cited by 31

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism

Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835510 · Cited by 28

New oncologic emergencies: What is there to know about inmunotherapy and its potential side effects?

Barquín, A., Molina‐Cerrillo, J., Garrido, P., Garcia-Palos, D., Carrato, A., & Alonso‐Gordoa, T. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.05.020 · Cited by 31

Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature

Chauhan, A., Burkeen, G., Houranieh, J., Arnold, S. M., & Anthony, L. B. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx213 · Cited by 27

Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy

Brumbaugh, A. D., Narurkar, R., Parikh, K., Fanucchi, M. P., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000217 · Cited by 25

Management of immune-related adverse events resulting from immune checkpoint blockade

Baroudjian, B., Arangalage, D., Cuzzubbo, S., Hervier, B., Lebbé, C., Lorillon, G., Tazi, A., Zalcman, G., Bouattour, M., Lioté, F., et al. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1562342 · Cited by 28

Use of new and emerging cancer drugs: what the cardiologist needs to know

Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 26

The role of immune checkpoints PD-1 and CTLA-4 in cardiovascular complications leading to heart failure

Huang, S., Kang, Y., Liu, T., Xiong, Y., Yang, Z., & Zhang, Q. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1561968 · Cited by 28

The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor–associated myocarditis

Zhao, S., Yun, H., Chen, C., Chen, Y., Lin, J., Zeng, M., Liu, T., Pan, C., & Jin, H. M. (2022) · European Radiology · doi:10.1007/s00330-022-08844-x · Cited by 24

Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature

Boutros, A., Bottini, A., Rossi, G., Tanda, E. T., Spagnolo, F., Barletta, G., Croce, E., Fava, P., Parisi, A., de Rosa, F., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.100791 · Cited by 26

Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature

Matsuo, K., Ishiguro, T., Najama, T., Shimizu, Y., Kobayashi, Y., & Mutou, M. (2019) · Internal Medicine · doi:10.2169/internalmedicine.2596-18 · Cited by 24

Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study

Zhang, C., Chen, Z., Qin, S., Zhu, Y., Shu, L., & Zuo, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1052699 · Cited by 19

Heart failure in cancer: role of checkpoint inhibitors

Delgobo, M., & Frantz, S. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.10.07 · Cited by 17

Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1

Manolis, A. S., Manolis, T. A., Mikhailidis, D. P., & Manolis, A. S. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1513488 · Cited by 17

Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management

Zarifa, A., Kim, J. W., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., & Kim, P. Y. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0089 · Cited by 17

Managing Select Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors

Cheema, P. K., Iafolla, M. A. J., Abdel-Qadir, H. M., Bellini, A. B., Chatur, N., Chandok, N., Comondore, V. R., Cunningham, M. E., Halperin, I. J., Hu, A. C., et al. (2024) · Current Oncology · doi:10.3390/curroncol31100473 · Cited by 18

Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

Somasundaram, A., & Burns, T. F. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s105678 · Cited by 15

Immune Checkpoint Inhibitors–Related Cardiotoxicity

Konala, V. M., Adapa, S., & Aronow, W. S. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000988 · Cited by 15

Immune-Checkpoint Inhibitor-Related Myocarditis: Where We Are and Where We Will Go

Vergara, A., Felice, M. D., Cesaro, A., Gragnano, F., Pariggiano, I., Golia, E., Pasquale, A. D., Blasi, E., Fimiani, F., Monda, E., et al. (2023) · Angiology · doi:10.1177/00033197231201929 · Cited by 17

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects

Zou, W., Lü, J., & Yan, H. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s311616 · Cited by 12

Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report

Sakai, T., Yahagi, K., Hoshino, T., Yokota, T., Tanabe, K., Mori, M., & Ikeda, S. (2019) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2019.100839 · Cited by 13

Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis

Zhang, C., Qin, S., & Zuo, Z. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211027339 · Cited by 13

Cardiac Myosin-Specific Autoimmune T Cells Contribute to Immune Checkpoint Inhibitor-Associated MyocarditisPreprint

Won, T., Kalinoski, H. M., Wood, M. K., Hughes, D. M., Jaime, C. M., Talor, M. V., Lasrado, N., Reddy, J., & Čiháková, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4065075 · Cited by 12

Immune Mechanisms of Viral, Autoimmune, and Immune Checkpoint Inhibitor‐Associated Myocarditis

Jo, W., Sun, V., & Čiháková, D. (2026) · Immunological Reviews · doi:10.1111/imr.70111 · Cited by 12

Immune-related adverse events of immune checkpoint inhibitors

Tadano, H., & Torigoe, T. (2017) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.40.102 · Cited by 11

Immune Checkpoint Inhibitor-Associated Myocarditis: From Pathophysiology to Rechallenge of Therapy – a Narrative Review

Tedeschi, A., Camilli, M., Ammirati, E., Gentile, P., Palazzini, M., Conti, N., Verde, A., Masciocco, G., Foti, G., Giannattasio, C., et al. (2023) · Future Cardiology · doi:10.2217/fca-2022-0120 · Cited by 13

Nivolumab in squamous cell carcinoma of the head and neck

Specenier, P. M. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1456337 · Cited by 10

Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma

Chang, A., Nasti, T. H., Khan, M. K., Parashar, S., Kaufman, J. L., Boise, L., Lonial, S., Ahmed, R., & Nooka, A. K. (2018) · Journal of Oncology Practice · doi:10.1200/jop.18.00208 · Cited by 11

Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis

Zhao, S., Yun, H., Chen, C., Chen, Y., Lin, J., Zeng, M., Liu, T., Pan, C., & Jin, H. M. (2022) · European Journal of Radiology · doi:10.1016/j.ejrad.2022.110558 · Cited by 9

La myocardite : une toxicité rare mais grave sous immunothérapie

Courand, P., Bouali, A., Harbaoui, B., Cautela, J., Thuny, F., & Lantelme, P. (2019) · Bulletin du Cancer · doi:10.1016/j.bulcan.2019.09.003 · Cited by 9

Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects

Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023) · Oncology Reviews · doi:10.3389/or.2023.11456 · Cited by 8

Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis

Thakker, R. A., Lee, M. A., Albaeni, A., Elbadawi, A., Suthar, K. H., Perez, C., Sonstein, L. K., Farr, N. M., Venkatesan, R., Khalife, W. I., et al. (2021) · Cardiology Research · doi:10.14740/cr1319 · Cited by 9

Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response

Stefanovic, F., Gomez‐Caminero, A., Jacobs, D. M., Subramanian, P., Puzanov, I. J., Chilbert, M. R., Feuerstein, S. G., Yatsynovich, Y., Switzer, B., & Schentag, J. J. (2022) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s369008 · Cited by 8

Global epidemiology of myocarditis: disparities in age, sex and geography

Klingel, K., Tschöpe, C., Yon, D. K., Mensah, G. A., Weber, B. N., Kontorovich, A., Lee, S., Cooper, L. T., & Ammirati, E. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01276-w · Cited by 9

A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents

Duarte, T., Costa, C., Gonçalves, S., Raposo, L., Ferreira, A. M., Albuquerque, C., Vau, N., & Caria, R. (2022) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.03.013 · Cited by 7

Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review

Gul, R., Shehryar, M., Mahboob, A., Kareem, H. K., Inayat, A., Safi, D., & Kamran, A. S. (2024) · Cureus · doi:10.7759/cureus.52952 · Cited by 7

Clinical and Advanced MRI Techniques for Detection of Checkpoint Inhibitor Associated Myocarditis

Arbune, A., Soufer, A., & Baldassarre, L. A. (2020) · Current Cardiovascular Imaging Reports · doi:10.1007/s12410-019-9521-5 · Cited by 6

An update on the safety of nivolumab for the treatment of advanced melanoma

Czarnecka, A. M., & Rutkowski, P. L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1757068 · Cited by 6

The Good (Tumor Killing) and the Bad (Cardiovascular Complications) of Immunologic Checkpoint Inhibitors

Gamero, M. T., Patel, A., & Storozynsky, E. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02147-x · Cited by 5

Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data

Papanikolopoulou, A., Michalopoulou, H., Kyriakoulis, K. G., Alexiou, P., Syrigos, N. K., Vathiotis, J., Thomopoulos, C., & Charpidou, A. G. (2025) · Cureus · doi:10.7759/cureus.87049 · Cited by 7

Chronic Anthracycline-related Myocarditis Presenting as Diffuse Myocardial Calcification

Pejic, M., Shifman, M., Rose, T. A., & Jeong, D. K. (2019) · Journal of Clinical Imaging Science · doi:10.25259/jcis_113_2019 · Cited by 5

What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications

Frayberg, M., Yung, A., Zubiri, L., Zlotoff, D. A., & Reynolds, K. L. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00844-1 · Cited by 5

Successful management of camrelizumab-induced immune-checkpoint-inhibitors-related myocarditis

Long, H., Du, Y., Wang, L., Liu, G.-C., Liang, S.-X., Zeng, Z., & Lin, Y.-E. (2023) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552231216104 · Cited by 4

Immune Checkpoints and Their Inhibition in T-Cell Lymphomas

Seňavová, J., Rajmonová, A., Heřman, V., Jura, F., Velasova, A., Hamová, I., Tkachenko, A. S., Kupcová, K., & Havránek, O. (2024) · Folia Biologica · doi:10.14712/fb2024070030123 · Cited by 4

Effets secondaires rhumatologiques immuno-induits par les inhibiteurs de points de contrôle de la réponse immunitaire

Tingry, T., Massy, E., Piperno, M., Auroux, M., Kostine, M., Maillet, D., Amini‐Adlé, M., Fabien, N., Estublier, C., Gonçalves, D., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.01.016 · Cited by 4

Checkpoint blockade-related CNS adverse events are characterized by neurotoxic T helper cells with sustained neuroantigen reactivity

Ma, Y. N., Zhang, A., Lin, J. F., Ding, F., Wang, X., Wang, W., Jian, G., Zhang, J., Zhu, P., Ma, Y. N., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102700 · Cited by 2

A case of sustained ventricular tachycardia due to pembrolizumab

Toyoshi, H., Yumoto, K., Yamanaka, K., Iwata, T., Koda, M., & Takatsu, H. (2019) · HeartRhythm Case Reports · doi:10.1016/j.hrcr.2019.08.009 · Cited by 2

Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines

Czarnecka, A. M., Kleibert, M., Płachta, I., Rogala, P., Wągrodzki, M., Leszek, P., & Rutkowski, P. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175182 · Cited by 2

Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: A case report

Alkhathlan, A. Z., Tofovic, D. S., Sullivan, C., Gupta, A., & Rajagopalan, S. (2017) · Case Reports in Internal Medicine · doi:10.5430/crim.v4n3p57 · Cited by 2

[Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis].

Liu, Y., Chen, Y., Zeng, Z., & Liu, A. (2021) · PubMed · doi:10.3779/j.issn.1009-3419.2021.102.27 · Cited by 1

Myocarditis Induced by Immunotherapy: A Rare but Fatal Complication

Mulendelé, P. M., Njie, M., Charfo, M., Lukifimpa, G. M., Boutar, M. S., Ovaga, B. E., HABOUB, M., Arous, S., Benouna, M. G., Drighil, A., et al. (2023) · Cardiology and Angiology An International Journal · doi:10.9734/ca/2023/v12i4360 · Cited by 1

Acute myocarditis and pericarditis after nivolumab treatment in patients with non-small cell lung cancer

Sakai, T., Sasada, S., Jyo, C., Ishioka, K., Takahashi, S., & Nakamura, M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx697.072 · Cited by 8

A Case of Acute Myocarditis During Treatment With Anti-PD-1 Antibody Nivolumab in a Melanoma Patient

Tadokoro, T., Keshino, E., & Mohri, M. (2016) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2016.07.355 · Cited by 2

Acute lymphocytic myocarditis.

Ganji, M., Ruiz-Morales, J., & Ibrahim, S. (2018) · Europe PMC (PubMed Central) · doi:10.11909/j.issn.1671-5411.2018.07.009 · Cited by 6

Fatal Myocarditis Following Treatment with the PD ‐1 Inhibitor Nivolumab

Matson, D. R., Accola, M. A., Rehrauer, W. M., & Corliss, R. F. (2017) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13633 · Cited by 72

Acute Myocarditis and Myositis Associated With Nivolumab Therapy

Mehta, A., Desai, N. K., & Ginsberg, F. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.08.096 · Cited by 2